On July 13, 2022, the Board of Directors of Entera Bio Ltd. appointed Miranda J. Toledano, one of the Company's existing directors and the Company's Chief Business Officer, Chief Financial Officer and Head of Corporate Strategy, as the Company's Chief Executive Officer (principal executive officer), which appointment became effective on July 15, 2022 concurrently with the effectiveness of the separation from the Company of Dr. Spiros Jamas. Ms. Toledano, who is 45 years old, has served as a member of the Board since September 2018, as a Member of the Scientific Advisory Committee of the Board since February 2022 and has been the Company's Chief Business Officer, Chief Financial Officer and Head of Corporate Strategy since May 2022. Ms. Toledano has over 20 years of strategic C-level leadership, principal investment and Wall Street and capital market experience in the biotech sector.

Previously, Ms. Toledano served as Chief Operating Officer, Chief Financial Officer and Director of TRIGR Therapeutics, an oncology focused, clinical stage bispecific antibody company acquired by Compass Therapeutics in June 2021. At TRIGR, Ms. Toledano oversaw the clinical development of lead asset TR009 (now CTX-009) and led strategic execution, including a $117 million China License Transaction and acquisition by CMPX. Previously, Ms. Toledano served as Head of Healthcare Investment Banking at MLV & Co, where she completed biotech equity financings (IPOs, ATMs, and follow-ons) totaling over $4 billion in aggregate value.

Earlier in her career, Ms. Toledano served as vice president in the investment group of Royalty Pharma.  Ms. Toledano is also a member of the board of directors of Journey Medical and NEXGEL. Ms. Toledano holds a B.A. in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business. On July 13, 2022, the Company and Dr. Spiros Jamas, the Company's former Chief Executive Officer, entered into a mutual separation agreement, pursuant to which the parties agreed that Dr. Jamas would resign from his position as the Company's Chief Executive Officer, effective July 15, 2022.